Abstract:N 6 -methyladenosine (m 6 A) RNA modification is a reversible mechanism that regulates eukaryotic gene expression. Growing evidence has demonstrated an association between m 6 A modification and tumorigenesis and response to immunotherapy. However, the overall influence of m 6 A regulators on the tumor microenvironment and their effect on the response to immunotherapy in lung adenocarcinoma remains to be explored. Here, we comprehensively analyzed the m 6 A modification patterns of 936 lung adenocarcinoma samples based on 24 m 6 A regulators. First, we described the features of genetic variation in these m 6 A regulators. Many m 6 A regulators were aberrantly expressed in tumors and negatively correlated with most tumor-infiltrating immune cell types. Furthermore, we identified three m 6 A modification patterns using a consensus clustering method. m 6 A cluster B was preferentially associated with a favorable prognosis and enriched in metabolism-associated pathways. In contrast, m 6 A cluster A was associated with the worst prognosis and was enriched in the process of DNA repair. m 6 A cluster C was characterized by activation of the immune system and a higher stromal cell score. Surprisingly, patients who received radiotherapy had a better prognosis than patients without radiotherapy only in the m 6 A cluster C group. Subsequently, we constructed an m 6 A score model that qualified the m 6 A modification level of individual samples by using principal component analysis algorithms. Patients with high m 6 A score were characterized by enhanced immune cell infiltration and prolonged survival time and were associated with lower tumor mutation burden and PD-1/CTLA4 expression. The combination of the m 6 A score and tumor mutation burden could accurately predict the prognosis of patients with lung adenocarcinoma. Furthermore, patients with high m 6 A score exhibited greater prognostic benefits from radiotherapy and immunotherapy. This study demonstrates that m 6 A modification is significantly associated with tumor microenvironment diversity and prognosis. A comprehensive evaluation of m 6 A modification patterns in single tumors will expand our understanding of the tumor immune landscape. In addition, our m 6 A score model demonstrated that the level of immune cell infiltration plays a significant role in cancer immunotherapy and provides a basis to increase the efficiency of current immune therapies and promote the clinical success of immunotherapy.

Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma